Afficher la couverture 'Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant | Demaria, Olivier' en grand format
/5

0 avis

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant

Archive ouverte

Demaria, Olivier | Gauthier, Laurent | Vetizou, Marie | Blanchard Alvarez, Audrey | Vagne, Constance | Habif, Guillaume | Batista, Luciana | Baron, William | Belaïd, Nourhène | Girard-Madoux, Mathilde | Cesari, Cedric | Caratini, Melody | Bosco, Frédéric | Benac, Olivier | Lopez, Julie | Fenis, Aurore | Galluso, Justine | Trichard, Sylvia | Carrette, Barbara | Carrette, Florent | Maguer, Aurélie | Jaubert, Solène | Sansaloni, Audrey | Letay-Drouet, Robin | Kosthowa, Camille | Lovera, Naouel | Dujardin, Arnaud | Chanuc, Fabien | Le Van, Mélanie | Bokobza, Sivan | Jarmuzynski, Nicolas | Fos, Camille | Gourdin, Nicolas | Remark, Romain | Lechevallier, Eric | Fakhry, Nicolas | Salas, Sébastien | Deville, Jean-Laurent | Le Grand, Roger | Bonnafous, Cécile | Vollmy, Lukas | Represa, Agnès | Carpentier, Sabrina | Rossi, Benjamin | Morel, Ariane | Cornen, Stéphanie | Perrot, Ivan | Morel, Yannis | Vivier, Eric

Edité par CCSD ; Cell Press -

International audience. Harnessing innate immunity is emerging as a promising therapeutic approach in cancer. We report here the design of tetraspecific molecules engaging natural killer (NK) cell-activating receptors NKp46 and CD16a, the β-chain of the interleukin-2 receptor (IL-2R), and a tumor-associated antigen (TAA). In vitro, these tetraspecific antibody-based natural killer cell engager therapeutics (ANKETs) induce a preferential activation and proliferation of NK cells, and the binding to the targeted TAA triggers NK cell cytotoxicity and cytokine and chemokine production. In vivo, tetraspecific ANKETs induce NK cell proliferation and their accumulation at the tumor bed, as well as the control of local and disseminated tumors. Treatment of non-human primates with CD20-directed tetraspecific ANKET leads to CD20+ circulating B cell depletion, with minimal systemic cytokine release and no sign of toxicity. Tetraspecific ANKETs, thus, constitute a technological platform for harnessing NK cells as next-generation cancer immunotherapies.

Suggestions

Du même auteur

Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis

Archive ouverte | Carvelli, Julien | CCSD

International audience. Coronavirus disease 2019 (COVID-19) is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in a pandemic1. The C5a complement fact...

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

Archive ouverte | Gauthier, Laurent | CCSD

International audience. Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecif...

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Archive ouverte | Andre, Pascale | CCSD

International audience. Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor ...

Chargement des enrichissements...